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Clostridioides difficile is recognized as one of the most important pathogens in 
hospital and community healthcare settings. The clinical outcome of infection of toxigenic 
C. difficile infection (CDI) ranges from asymptomatic colonization to fulminant 
pseudomembranous colitis and death. In recent studies, it has been suggested that a high 
proportion of nosocomial CDI cases are transmitted from asymptomatic carriers which 
might be acting as infection reservoirs. Understanding what causes the different responses 
to infection could lead to the development of novel prevention and treatment strategies. 
Although several explanations have been proposed to explain variations in susceptibility, 
understanding of the exact mechanisms that underlie the spectrum of variation in CDI 
disease severity remains limited and further research is needed to determine what factors 
are responsible for these variations. In this work, we establish different human microbiota-
associated (HMA) mouse models. By analyzing innate immune responses to CDI, we 
demonstrate that these models reproduce differences in disease severity during infection 
observed in human patients.  These differences were largely based on mouse strain 
(C3H/HeN and C57BL/6J) and independent from C. difficile burden or toxin activity. 
Altogether, our HMAmouse models demonstrated the potential to study interactions between 
microbiome, pathogen and host inflammatory responses in the context of CDI. 
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CHAPTER 1. UNDERSTANDING DISEASE OUTCOMES FOLLOWING 
INFECTION WITH THE GASTROINTESTINAL PATHOGEN, 
CLOSTRIDIOIDES DIFFICILE 
 
1.1 INTRODUCTION  
C. difficile is a spore-forming, toxin-producing, Gram-positive anaerobic bacillus that 
causes infectious diarrhea and colitis primarily in health care settings; it is generally 
associated with the disruption of a “healthy” gut microbiome caused by antibiotic 
consumption and can cause infections that range from mild diarrhea to 
pseudomembranous colitis and potential death (Crobach et al., 2018; Collins & 
Auchtung, 2017). The rise in frequency of C. difficile infections that occurred during the 
first decade of the 21st century led to major concerns about the impact C. difficile 
infections have upon public health and renewed interest in the pathogenesis of C. difficile 
infection (CDI). While strategies to reduce disease transmission have had some success 
in reducing rates of infection (Al-Omari et al., 2020; Morgan et al., 2019), CDI remains 
one of the most common causes of hospital acquired infections and is one of only six 
antibiotic-resistant pathogens designated by the Centers for Disease Control as an urgent 
threat to public health (2019 CDC report). This review will discuss the history and 
pathogenicity of C. difficile, describe variations in disease outcome and summarize 
current understanding of potential mechanisms that influence disease severity. In 
addition, I will examine the role of the host inflammatory responses to CDI in depth to 
introduce the main focus of this thesis. 
1.2 C. DIFFICILE INFECTION AND DISEASE 
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1.2.1 Burden to public health 
C. difficile infection has become the leading infectious cause of nosocomial 
diarrhea in developed countries over the past 20 years , especially in healthcare facilities 
where C. difficile-related excess medical costs were estimated to be as much as one 
billion dollars in the United States annually presenting a significant financial burden on 
the healthcare system (Czepiel et al., 2019; CDC, 2019). Asymptomatic carriers, infected 
patients, contaminated environments and some farm animals are potential infection 
reservoirs for C. difficile (Lim et al., 2020; Bauer & Kuijper, 2015; Knetsch et al., 2014; 
Samore et al., 1996). Prevalence of C. difficile in these reservoirs can be undetectable 
without strict surveillance. 
1.2.2 History of disease  
Although C. difficile was identified in healthy neonates in the 1930s, it was not 
considered a pathogenic organism until the late 1970s when Bartlett and colleagues 
isolated C. difficile from the stool of patients with pseudomembranous colitis and 
demonstrated its cytotoxicity in vitro and in a hamster model of disease (Hall & O’Toole, 
1935; Bartlett et al., 1978). Previously, C. difficile was rarely found in the normal 
intestinal microbiomes of adults, but as the use of antibiotics increased, its role in the 
pathogenesis of intestinal diseases became more evident (George et al., 1978; Larson et 
al., 1978). During the last two decades of the twentieth century, C. difficile’s clinical 
relevance was limited to mild and easily controlled cases; however, the incidence and 
severity of C. difficile infection steadily increased at the beginning of the twenty-first 
century. Increased incidence of infection, disease severity and mortality levels were 
linked to the emergence of a new C. difficile lineage,  epidemic ribotype 027 C. difficile 
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(alternatively referred restriction endonuclease analysis group BI or North American 
pulsed-field electrophoresis 1 or NAP1/BI/027), that was responsible for several 
outbreaks in North America and Europe (Pepin et al., 2005; Warny et al., 2005, He et al., 
2013; McDonald et al., 2005). This ribotype showed high level fluoroquinolone 
resistance, production of a binary toxin previously rare in C. difficile strains and was 
described as hypervirulent due to increased disease severity typically observed in patients 
infected with this ribotype. (Warny et al., 2005; Cowardin et al., 2016; He et al., 2013; 
Spigaglia et al., 2008). Some initial studies pointed to increased sporulation efficiency 
and production of higher levels of toxins as possible factors contributing to 
hypervirulence, although later studies indicated that both sporulation efficiency and 
levels of toxin produced vary among ribotype 027 isolates. Subsequent studies 
highlighted increased fitness and expanded metabolic capacity as potential factors that 
led to the emergence of ribotype 027 strains (Robinson et al., 2014; Collins et al., 2018). 
While some regions have seen declines in the prevalence of infections caused by ribotype 
027 strains (Freeman et al., 2020; Eyre et al., 2018), other ribotypes have increased in 
prevalence and C. difficile infection remains one of the most common hospital acquired 
infections (Lessa et al., 2015). 
1.2.3 Pathogenicity of toxins.  
C. difficile enters the body through the ingestion of spores that can be transmitted 
environmentally or from other patients via fecal-oral route; these spores are able to 
survive the acidic conditions of the stomach and germinate into vegetative cells once they 
reach the distal small intestine (Lessa et al., 2012; Sorg & Sonenshein, 2008). The 
primary site of disease during C. difficile infection is the human colon; the anoxic 
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environment in the lumen permits obligate anaerobic bacteria such as C. difficile to 
survive and, under the right conditions, proliferate and produce enterotoxins that damage 
the intestinal epithelium in several ways (Smits et al., 2016). Disease is primarily 
mediated by two virulence factors, toxins A and B, which are encoded by tcdA and tcdB 
genes (Fig. 1.1a) (Kuehne et al., 2010). These genes form a chromosomal pathogenicity 
locus with two regulatory genes tcdC and tcdD in addition to a tcdE porin gene (Govind 
& Dupuy, 2012). Both toxins are glucosyl transferases that bind to the surface of the 
intestinal epithelial cells where they are internalized; once internalized, they catalyze the 
glucosylation of small GTPase proteins of the Rho and Rac family, irreversibly 
inactivating them (Pruitt & Lacy, 2012). The activity of the toxins leads to 
depolymerization of the epithelial actin cytoskeleton, disruption of tight junctions and 
severe epithelial damage due to apoptosis; these mechanisms of compromising intestinal 
membrane integrity make the host susceptible to transmission of intestinal 
microorganisms across the epithelial barrier, while also promoting activation of an 
inflammatory response in the form of cytokines and chemokine production and 
neutrophil recruitment (Fig. 1.1b) (Abt et al., 2016; Voth & Ballard, 2005; Kelly & Kyne, 
2011).  
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The potential relative contribution of tcdA and tcdB in C. difficile pathogenesis in 
vivo has been investigated in different animal models. In mouse and human colonic 
organoids, it has been shown that C. difficile strains that lack functional TcdA activity 
(such as strains in RT017) can induce severe damage to the colonic epithelium and cause 
a dysfunctional stem cell state that impairs epithelial homeostasis by relying solely on a 
TcdB-mediated process (Lyras et al., 2009; Mileto et al., 2020). Further, infection of 
humans with RT017 strains results in clinical disease, indicating that TcdA is not 
required for pathogenesis. However, deletion mutagenesis studies have shown that 
deletion of either tcdA or tcdB reduce pathogenicity, leading to conflicting interpretations 
 
 
Figure 1.1 Pathogenicity of C. difficile toxins (a) The indigenous microbiota and its ability to 
protect against pathogens and other harmful agents can be dramatically reduced by antibiotic 
treatments. Once a susceptible host becomes exposed to C. difficile spores, the favorable 
environment allows spores to germinate, colonize and subsequently produce enterotoxins that 
damage the intestinal epithelium. (b) C. difficile toxins A and B glucosylate and thereby 
inactivate RHO or RAC GTPases resulting in the breakdown of tight junctions and loss of 
epithelial integrity leading to inflammation and increased permeability of the host epithelium. 
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of whether both TcdA and TcdB were required to cause disease or could independently 
contribute to disease progression (Lyras et al., 2009, Kuehne et al., 2010). The 
inconsistent findings point to virulence differences resulting from variations in C. difficile 
strains, experimental animal models, host microbiota composition and antibiotic 
sensitivity. Overall, it has been demonstrated that TcdB has a major role mediating 
inflammation and mortality in the murine model and that TcdA has a lighter 
inflammation impact in mice but is slightly more toxic in hamsters (Carter et al., 2015). 
Whether TcdA increases the severity of human disease is currently unknown; there have 
been no known outbreaks caused by strains that encode only TcdA. 
In addition, a different binary toxin (also known as C. difficile transferase CDT) 
has also been associated with severe CDI development in some C. difficile strains 
(primarily epidemic ribotypes 027 and 078). This binary toxin ADP-ribosylates actin 
leading to disruption of the actin cytoskeleton (Gerding, 2014; Abt et al., 2016). Binary 
toxin is encoded by chromosomal genes cdtA and cdtB, which are distinct from the 
chromosomal tcd pathogenicity locus (Gerding, 2014; Abt et al., 2016). However, the 
role of binary toxin in virulence remains unclear (Czepiel et al., 2019).  
1.2.4 Range of clinical outcomes 
Not all patients who become infected with C. difficile develop the associated 
disease. Once a susceptible individual is exposed to C. difficile, a wide range of clinical 
disease outcomes can occur. It has been documented that up to 20% of susceptible 
individuals who become colonized do not develop diarrhea, and up to two thirds of 
patients with nosocomial C. difficile colonization were asymptomatic for disease 
(McFarland, et al., 1989; Buggy, et al., 1983). On the other hand, most patients that 
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develop C. difficile infection experience mild diarrhea after an incubation period of 2-3 
days; a longer incubation period might also occur, but it varies from person-to-person 
(McFarland et al., 1989; Samore et al., 1994). Some C. difficile infected patients develop 
abdominal pain, fever, nausea, vomiting, weakness, and loss of appetite generally during 
or directly after antimicrobial therapy. In the most severe cases, life-threatening 
symptoms such as dehydration, abdominal distention, hypoalbuminemia with peripheral 
edema and subsequent circulatory shock can occur leading to severe complications in the 
form of toxic megacolon, colon perforation, kidney failure, systemic inflammatory 
response syndrome, septicemia or death (McDonald et al., 2018). Although potential 
explanations for the variations in susceptibility and disease progression have been 
proposed, the mechanisms that modulate C. difficile infection outcome remain poorly 
understood and are the focus of ongoing investigations.  
1.3 C. DIFFICILE CARRIAGE/COLONIZATION 
 
1.3.1 Colonization resistance and disruption by antibiotic use. 
Antibiotic use is a primary risk factor for developing C. difficile infection; this 
increased risk for infection is likely due to disruption of the indigenous microbiome and 
subsequent loss of colonization resistance (Abt et al., 2016). One mechanism through 
which antibiotic treatments alter colonization resistance is to alter the intestinal 
metabolome (the metabolic products produced by the GI microbiome) which creates a 
suitable environment for C. difficile growth (Theriot et al., 2014). For instance, 
commensal bacteria can release sialic acid from digestion of host intestinal mucous and 
convert complex carbohydrates into short-chain fatty acids, two metabolites that are 
quickly consumed by other members of the microbiome as energy sources (Ng et al., 
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2013). However, antibiotic consumption can reduce the number of these competing 
bacteria causing an excess abundance of those metabolites which C. difficile is able to use 
for growth in the absence of competing organisms (Ferreyra et al., 2014; Theriot et al., 
2014; Ng et al., 2013; Wilson & Perini, 1988). Other interactions between the commensal 
microbiome and C. difficile can also limit proliferation, such as bacteriocin production  
(Corr et al., 2007; Rea et al., 2011). In addition, interactions between the gastrointestinal 
microbiome and host immune response can influence susceptibility to C. difficile 
infection and can be disrupted by antibiotic treatment; these interactions will be discussed 
in more detail below (Abt et al., 2016). Therefore, the ability of C. difficile to colonize 
the large intestine can be repressed by both direct and indirect mechanisms of the 
intestinal microbiome which are disrupted under antibiotic treatments. Most antibiotics 
have been associated with the development of C. difficile infection, including those that 
are used for treatment. The use of broad spectrum antibiotics, such as penicillins and 
cephalosporins, clindamycin and fluoroquinolones, has a much higher risk of making the 
host susceptible to C. difficile infection than other antibiotics (Leffler & Lamont, 2015). 
By restoring the microbiome, through fecal transplantation, the host can re-establish the 
resistance mechanisms that inhibit C. difficile colonization (van Nood et al., 2013). 
1.3.2 Potential mechanisms of asymptomatic carriage/colonization 
Several recent studies have documented that, in contrast with a widely held 
assumption, a large proportion of hospital associated CDI cases are not due to 
transmission from other symptomatic CDI cases, but rather from asymptomatic carriers 
(Curry et al., 2013; Didelot et al., 2012). Although the definition varies among studies, 
asymptomatic carriers or asymptomatically colonized patients are patients where C. 
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difficile and its toxins are detected in stool, but no clinical symptoms appear (Furuya-
Kanamori et al., 2015; Crobach et al., 2018). This subset of individuals usually remains 
undetected unless strict surveillance and infection control methods are implemented. 
These patients can potentially act as an infection reservoir contributing significantly to 
the chain of transmission (Didelot et al., 2012; Ziakas et al., 2015; Cohen et al., 2010). 
Current practice largely underestimates the importance of detecting asymptomatic C. 
difficile colonization in healthcare settings and improvements are needed to minimize the 
risks of infection caused by asymptomatic patients (Ziakas et al., 2015). 
It is not known why toxigenic strains, despite being able to colonize and produce 
toxins in susceptible individuals, cause severe disease in some patients but not in others. 
However, potential explanations have been proposed; these explanations include the fact 
that non-toxigenic C. difficile strains or non-pathogenic organisms could be outcompeting 
toxigenic C. difficile strains and allowing them to persist at levels too low to cause 
disease and/or that differences in immune responses and other host factors could allow 
asymptomatic colonization in some individuals and not in others (Britton & Young, 
2012). 
The potential to use a non-toxigenic C. difficile strain as a competitor to toxigenic 
strains has been proposed as a novel prevention and treatment strategy. Pre-colonization 
with these organisms could exclude toxigenic C. difficile strains by outcompeting them a 
nutritional niche; in addition, non-toxigenic strains could inhibit toxigenic C. difficile 
germination or growth (Sambol et al., 2002). However, Brouwer and colleagues found 
that transconjugation of the pathogenicity locus from toxigenic to non-toxigenic C. 
difficile strains is possible (Brouwer et al., 2013), indicating that broad-scale 
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implementation of this approach may not reduce the overall rates of symptomatic C. 
difficile infection. 
Other research groups have found that differences in microbiota such as 
enrichment of Eubacterium species and Clostridium species other than C. difficile 
distinguish between symptomatic and asymptomatic infection and might have a role in 
determining disease outcome either by regulating levels of C. difficile and/or its toxin or 
by blocking pathogenic interactions with the host epithelium or immune system (Zhang et 
al., 2015; Vincent et al., 2016). Buffie and colleagues were able to identify the 
commensal species Clostridium scindens, which promotes conversion from primary bile 
acids to secondary bile acids, as a C. difficile infection-resistant organism, but also 
concluded that bile acids may not be the only metabolites having a role in the inhibition 
of C. difficile expansion (Buffie et al., 2015). 
In addition, substantial evidence has arisen that asymptomatic C. difficile 
colonization has a protective effect against progression to disease through an immune-
mediated response (Kelly et al., 2019). Hospitalized patients who later became 
asymptomatically colonized with C. difficile had higher levels of Immunoglobulin G 
(IgG) to toxin A upon admission than in patients that subsequently developed diarrhea. 
However, this was only observed in newly C. difficile-exposed patients (Kyne & Kelly, 
2000). Additionally, Kyne et al. found that patients that became colonized with C. 
difficile and presented low levels of serum IgG antibody against toxin A had a higher risk 
of developing C. difficile diarrhea (Kyne et al., 2000). Mulligan and colleagues observed 
that the mean optical density for IgA reactive with C. difficile somatic-cell antigens was 
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significantly lower in patients with symptoms than asymptomatic carriers (Mulligan et al., 
1993). A study on C57BL/6J mice found that a protective immune response against CDI 
was generated that included IgG and IgA serum anti-toxin antibodies, as well as mucosal 
IgA anti-toxin antibodies (Johnston et al., 2014).  
Yu et al. reported that CDI elicits a cascade of systemic cytokine production 
including upregulation of IL-1β, IL-8, IL-16, and IL-17A. These are main cytokines that 
could serve as markers that mediate C. difficile disease (Yu et al., 2017). In addition to 
these cytokines, upregulation of specific chemokines (Cxcl1, Cxcl2, Ccl2), IL-23, and 
antimicrobial peptides (Reg3g) have also characterized severe C. difficile infection in 
numerous human and mouse studies (Sadighi Akha et al., 2013; McDermott et al., 2014, 
2015, 2017). Neutrophil infiltration along with tissue damage are also prominent 
characteristics of patients with pseudomembranous colitis (McDermott et al., 2016). 
Evaluating these known responses in an asymptomatic colonization model of C. difficile 
could give us a greater insight into how host-specific immune response protect against 
severe CDI. 
 1.3.3 Microbiome modulation of the mucosal immune response and its 
impact on C. difficile associated disease 
As described above, C. difficile infection can initiate signaling cascades that result 
in pro-inflammatory cytokine and chemokine production (Hasegawa et al., 2011). This 
cytokine signaling also leads to neutrophil infiltration, a hallmark characteristic of C. 
difficile severe infection (Solomon et al., 2013). Further evidence for the role that 
neutrophils play in disease progression was obtained in studies with IL-23 knock out 
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mice where neutrophil infiltration was repressed and colonic histopathology was reduced 
(McDermott et al., 2016). However, transgenic mouse studies in which neutrophil 
infiltration was reduced have also shown decreased C. difficile clearance and an increased 
mortality rate (Jarchum et al., 2012; Hasegawa et al., 2011). This data suggests that the 
mechanisms through which neutrophil recruitment is modulated might have an essential 
role in balancing C. difficile clearance with excessive damage to the colonic epithelium. 
Data from additional mouse studies have demonstrated that timing and magnitude 
of immune responses might have a significant role in regulating C. difficile disease 
outcomes. Mice deficient in innate lymphoid cell (ILC) signaling rapidly succumb to 
disease following infection. This deficiency can be rescued through restoration of Type 1 
ILCs, suggesting that these cells can play a protective role during C. difficile infection 
(Abt et al., 2015). Signals produced by the commensal microbiome, most notably 
Bacteroides fragilis polysaccharide A, are known to promote ILC1 expansion through 
stimulation of dendritic cell secretion of IL-17 (Duan et al., 2010). Recruitment of 
eosinophils via IL-25 and IL-33 signaling also provide protection during CDI and are 
modified by the presence of the microbiome (Buonomo et al., 2016; Frisbee et al., 2019)). 
As described above, ILC3 responses promote (e.g., IL-23) and antagonize (e.g., IL-22) 
intestinal damage during C. difficile infection (Nagao-Kitamoto et al., 2020; Buonocore et 
al., 2010). Microbiome composition is known to regulate secretion of IL-22 and IL-23 as 
well as regulate the balance between activities of Th17 and regulatory T cells (Abt et al., 
2015; Atarashi et al., 2011; Ivanov et al., 2009; Mazmanian et al., 2008; Atarashi et al., 
2013). This regulation could also play a role in restoring immune homeostasis during 
resolution of C. difficile infection. 
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  From this data, it is clear that there are many mechanisms through which the 
microbiome could potentially modulate the activity of the immune response to C. difficile 
and influence the outcome of infection. Yet, further research is necessary for defining 
specific immune response pathways or other mechanisms of protection against disease. 
Studying these interactions will provide a better understanding of C. difficile 
pathogenesis potentially leading to better predictive modeling of disease progression and 
identification of new therapeutic targets to regulate disease outcome.  
 1.3.4 Mouse models of C. difficile associated disease 
Numerous animal models, including hamsters, rabbits, piglets, mice, and rats, 
have been used to evaluate CDI. Infection in these models can be initiated by a variety of 
antibiotic regimens followed by experimental challenge or simply environmental 
exposure to C. difficile (Best et al., 2012). The hamster model has been one of the most 
well described and extensively employed models to study CDI. The hamster model 
displays several pathophysiological features observed in humans. However, if left 
untreated, infection is rapidly fatal within the first 48 hours from infection. The observed 
rapid fatality is one of the key differences with human disease along with the fact that 
hamsters also generally do not develop diarrhea. Thus, the hamster model serves as a 
model to test interventions that prevent death. For this reason, many researchers have 
transitioned to mouse studies.  
As in human disease, mice develop intestinal pathology primarily involving the 
colon. It has also been reported that mice can exhibit a spectrum of disease that includes 
asymptomatic colonization (Chen et al., 2008), in contrast to the previously mentioned 
fulminant and highly lethal pathology shown on hamster models (Babcock et al., 2006; 
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Lusk et al., 1978). Given that the metabolic functionality and composition of the 
intestinal microbiota of conventional mice or other animal models vastly differ from the 
human gut microbiota in many aspects, gnotobiotic animals colonized with human 
microbiota might be a better model to help overcome those differences and have a more 
close resemblance of microbiome-host interactions in the context of CDI (Hirayama, 
1999; Tlaskalová-Hogenová et al., 2011). The human gut microbiota can retain its 
bacteriological and enzymatic characteristics when it is associated with gnotobiotic 
rodents, therefore the human microbiota-associated mice model is a convenient way to 
study causal relationships between relevant microbes to human disease and the host 
pathology (Licht et al., 2007; Hirayama et al., 1995; Du et al., 2015; Collins et al., 2015).  
In the context of CDI, the HMAmouse model has the potential to reveal important 
interactions between specific human fecal microbes, C. difficile and the host immune 
system that are important for the  disease pathology of CDI observed in human beings 
and facilitate studies on the potential mechanisms of protection against the severity of 
disease in humans.  
1.4 CONCLUSIONS  
C. difficile infection is an important threat to public health for which a better 
understanding of disease pathophysiology is highly needed. While many studies have 
made progress towards understanding microbiome-mediated mechanisms for preventing 
C. difficile colonization and toxin production, the role of host inflammatory responses to 
CDI and how they vary between symptomatic and asymptomatic disease are not fully 
understood. While, there is evidence of a major role of the innate immune system in 
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regulating disease severity, further research is needed to understand the exact 
mechanisms underlying variation in disease outcome. The work discussed in the 
following chapter will describe the work that I have done to develop and characterize 
appropriate mouse models for studying interactions of microbiome and host factors that 
contribute to differences in disease severity during CDI. 
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CHAPTER 2. DIFFERENCES IN IMMUNE RESPONSES CONTRIBUTE TO 
ALTERED LEVELS OF DISEASE SEVERITY BETWEEN C3H/HEN AND 
C57BL/6J MICE INFECTED WITH C. DIFFICILE 
2.1 ABSTRACT 
Clostridiodes difficile has become the leading infectious cause of antibiotic-
associated diarrhea in developed countries over the past 20 years. It has achieved a 
steadily rising global incidence of infection and with this, an increase in mortality, 
especially in hospitals and community healthcare settings. When a susceptible individual 
is exposed to C. difficile, multiple outcomes are possible, including asymptomatic 
colonization, mild diarrhea, pseudomembranous colitis, and death; however the 
mechanisms underlying these variations in disease severity are currently not fully 
understood. In this study, we established different human microbiota-associated (HMA) 
mouse models that demonstrated clear differences in disease severity after C. difficile 
exposure independent from C. difficile burden or toxin activity. We observed that mouse 
strain background (C3H/HeN and C57BL/6J) had the largest impact on disease outcome 
and that donor microbiome also influenced disease severity. Characterization of the initial 
inflammatory responses after infection revealed a clear difference in levels of 
inflammation during CDI based upon host genetic background. Altogether, the results of 
this study demonstrated the potential of the HMAmouse model to study interactions 
between microbiome and host inflammatory responses in the context of CDI. 
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2.2 INTRODUCTION 
Clostridioides difficile is the leading cause of nosocomial gastrointestinal 
infections and has been categorized as a serious public health problem due to its high 
rates of disease, morbidity and mortality over the last couple of decades (Martin et al., 
2016). C. difficile infection occurs after the ingestion of spores by a susceptible host, 
most commonly associated with antibiotic treatments that disrupt the host indigenous 
microbiome. However, the clinical manifestation of disease can range from mild to 
moderate diarrhea to severe life-threatening conditions that include pseudomembranous 
colitis, toxic megacolon, and death. However, the mechanisms underlying these 
variations in disease outcome are not known (Leffler & Lamont, 2015). 
While there have been substantial advances identifying commensal bacterial 
species and mechanisms that can prevent C. difficile colonization (Britton & Young, 
2012), the role of the host immune defenses and their interactions with the host 
microbiome in limiting disease severity are less well understood (Saleh & Petri, 2019). 
Evidence continues to be reported that supports the idea that the type of immune response 
mounted by the host against C. difficile infection has a major role in modulating severity 
and determining outcome of disease (El Feghaly et al., 2013; Saleh & Petri, 2019). 
Ultimately, a better understanding of the protective and pathogenic properties of immune 
responses during CDI is crucial to identify targets for potential immunotherapies and 
strategies for prevention (Saleh & Petri, 2019).  
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The innate immune signaling pathways linked to innate lymphoid cells (ILCs) 
have previously been associated with the early host defense to CDI (Abt et al., 2016). 
ILCs, which reside primarily at mucosal surfaces, largely maintain homeostasis with the 
indigenous microbiome by preventing harmful inflammatory responses to nonpathogenic 
microbes (Seo et al., 2020). ILCs also have a prominent role regulating the early 
responses to infections by different pathogenic microbes at mucosal barriers and 
contribute to clearance of pathogens and restoration of intestinal integrity after infection 
by rapid production of cytokine signaling (Britanova & Diefenbach, 2017).  
Functional subsets of ILCs have been identified where ILC1, ILC2 and ILC3 
share similarities in transcription factors and cytokine signatures with Th1, Th2 and Th17 
cells types respectively (Klose et al., 2014; Serafini et al., 2015; Walker et al., 2013). 
Type 1 ILCs secrete IFN-g which can increase phagocytic mechanisms. Loss of IFN-g 
signaling can lead to increased vulnerability to disease progression during C. difficile 
infection as shown by Abt and colleagues (Abt et al., 2015). Mouse studies have 
previously shown that Type 2 ILCs have a protective role against C. difficile. For 
example, interleukin 25 (IL-25), a cytokine regulated by Type 2 ILCs whose levels are 
also dependent on the microbiota, becomes suppressed during CDI; IL-25 restoration can 
induce eosinophil, basophil, and mast cell accumulation at sites of inflammation reducing 
mortality and tissue pathology (Buonomo et al., 2016).  Neutrophil infiltration, along 
with secretion of IL-1b, IL-17 and GM-CSF is characteristic of ILC type 3 immune 
responses. Neutrophil activation and tissue infiltration have long been considered a 
hallmark of C. difficile infection although neutrophils can have both protective and 
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pathogenic roles mainly due to the lack of target cell specificity (Kelly et al., 1994; Jose 
& Madan, 2016; Saleh & Petri, 2019). From these studies, it is clear that there are 
complex interacting roles for ILC1, ILC2 and ILC3 responses during infection and more 
work is needed to characterize how these pathways interact with each other and the 
microbiome to influence disease outcome during infection.  
Here, we establish different human microbiota-associated (HMA) mouse models 
that demonstrate clear differences in disease severity after C. difficile exposure 
independent from C. difficile burden or toxin activity. To develop these models, we 
colonized mice from two genetic backgrounds (C57BL/6J and C3H/HeN) with fecal 
microbiota from three healthy human donors. We observed that mouse strain background 
had the largest impact on disease outcome, as C57BL/6J mice showed the most severe 
manifestation of disease following infection. We also observed that donor microbiome 
influenced disease severity, with one donor microbiome leading to reduced disease 
severity in C57BL/6J mice compared to the other microbiomes tested. 
We focused on a subset of HMAmice colonized with a single human fecal sample 
that represented both an asymptomatic (C3H/HeN) and severe disease (C57BL/6J) 
presentation to characterize the initial inflammatory responses and the level of epithelial 
damage after infection. We hypothesized that severe disease would correlate with 
increased levels of inflammatory markers associated with ILC Type 3 responses, while a 
more protective effect would be due either to reduced levels of ILC Type 3 responses or 
upregulation of ILC Type 1 and 2 associated markers. We observed that several 
inflammation markers were highly upregulated in the C57BL/6J mice and expressed at 
lower levels in C3H/HeN mice. Only one inflammatory marker, IL-1β was induced at 
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higher levels in C3H/HeN mice. Thus, reduced disease severity in C3H/HeN mice appear 
to be primarily due to reduced activation of ILC Type 3 responses rather than 
upregulation of ILC Type 1 and 2 responses. Altogether, we demonstrate the potential of 
the HMAmouse models to study interactions between microbiome and host inflammatory 
responses in the context of CDI. 
2.3 MATERIALS AND METHODS 
2.3.1 Establishment of human-microbiota associated mice (HMAmice) 
Germ-free C57BL/6J and C3H/HeN were administered, via oral gavage, one of 
three human derived fecal microbiota samples (designated MA, MB and MC) that were 
collected from healthy donors (Donor A, B and C) that had not taken antibiotics for at 
least three months. Donors varied by age:  donor A was a person of advanced age (>65 
year old), donor B was a child (5-17), and donor C was an adult (18-65); information 
about sex of the donors was not collected. Samples were collected and administered 
under protocols approved by IRB panels at Baylor College of Medicine (H-38014) and 
the University of Nebraska-Lincoln (#18585). Samples were screened for C. difficile 
presence by selective plating on the C. difficile enrichment medium, taurocholate-
cefoxitin-cycloserine-fructose agar (TCCFA), to confirm their C. difficile-negative state. 
Following an initial establishment over the course of two weeks, mice were housed in 
individually ventilated cages with ad libitum access to autoclaved water and food and 
bred in a specific-pathogen-free facility where their microbiota was passed to their 
progeny. Sequencing of the V4 region of the 16S rRNA gene of representative progeny 
mice from each HMAmouse line (Appendix A) was used to analyze differences in 
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microbiome content such as relative taxa abundance, alpha and beta diversity measures as 
previously described (Auchtung et al., 2020). 
2.3.2 C. difficile infection experiments in HMAmice. 
In order to compare C. difficile colonization in HMAmouse models, we performed 
infection experiments by administering an antibiotic cocktail consisting of kanamycin 
(0.4 mg ml-1), gentamicin (0.035 mg ml-1), colistin (850 U ml-1), metronidazole (0.215 
mg ml-1), and vancomycin (0.045 mg ml-1) for 4 days in drinking water. A day after mice 
were transitioned to fresh water, a single intraperitoneal injection of clindamycin (10 
mg/kg) was administered as described by Collins and colleagues (Collins et al., 2015). 
Exposure to 104 spores of C. difficile ribotype 027 strain CD2015 spores via gavage 
followed after 24 hours from antibiotic treatment completion as previously described by 
Robinson (Robinson et al., 2014). Mice were monitored for weight loss, visible signs of 
disease such as hunched posture, loss of ambulation, presence of watery stool, and death 
for 3 or 7 days following initial C. difficile infection. A subset of mice was euthanized on 
day 3 to determine levels of histopathogical damage and/or to measure levels of immune 
responses during the peak of disease severity, as previous studies had demonstrated 
resolution of symptoms by day 7 of infection (Collins et al., 2015). Fecal samples were 
collected at different time points following infection to determine the levels of C. difficile 
colony forming units (CFU) and relative toxin units (RTU) per gram of feces as 
previously described (Auchtung et al., 2020).  
2.3.3 Measuring levels of C. difficile CFU and toxin activity present in fecal 
samples. 
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In order to determine the CFU of C. difficile present in mouse fecal samples, the 
fecal pellets were weighed and then homogenized in 0.5 ml anaerobic PBS, serially 
diluted at 1:10 dilutions and spot plated on TCCFA plates containing erythromycin and 
rifampicin that were previously pre-reduced in an anaerobic chamber. Plates were 
incubated at 37°C for 24-36 hrs. Colonies were counted and used to calculate the number 
of CFU/g of fecal mass. 
To measure the amount of relative toxin units (RTU)/g of feces in the mouse fecal 
samples, Vero cell cytotoxicity assays were carried out as described (Robinson et al., 
2014). Vero cells were grown to near confluence in 150 cm2 flasks in DMEM + 10% 
FBS in an incubator at 37°C with 5% CO2. Cells were trypsinized, seeded at 105 cells/ml 
into 96-well microtiter plates, and incubated for at least 4 hours at 37°C with 5% CO2. 
Fecal samples were weighed and resuspended in 0.5 ml sterile PBS, centrifuged, and their 
supernatants filtered through sterile 0.2 µm PVDF membranes. Filtrates were serially 
diluted and overlaid on the Vero cell seeded plates. Plates were incubated at 37°C with 
5% CO2 for 36-48 hours, and then examined for cell rounding. RTU were determined 
based upon the last dilution at which 80% of cells were rounded. RTU/g of feces were 
calculated using the recorded dilution factor. 
2.3.4 RNA isolation and expression analysis 
Cecal RNA was isolated from 1 cm cecal tissue sections collected at necropsy and 
stored in RNAlater (Thermo Fisher). Cecal tissue was homogenized and RNA was 
extracted with RNeasy Mini kit (Qiagen) according to manufacturer’s protocol with 
optional on-column DNase I digestion.  RNA concentration and purity were determined 
by measuring absorbance at A260 and A280. cDNA generation and qRT-PCR for relative 
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gene expression 
were performed 
using One-Step 
SuperScript III 
Platinum SYBR 
Green kit 
(Invitrogen) with 
2 µl RNA and the 
primer sets in 
Table 1 (1 µM 
final 
concentration) on 
a QuantStudio 5 
Real-Time PCR instrument (Thermo Fisher). The cycling conditions were: 3 minutes at 
50° C for cDNA synthesis, a denaturation step for 5 minutes at 95°C followed by 40 
cycles of 95°C for 15 seconds and at 60°C for 30 seconds, and a 1 minute hold step at 
40°C after. Relative expression levels between mice challenged with C. difficile and 
uninfected controls (n=1 uninfected control/mouse background) were determined using 
the 2−ΔΔCt method, and GAPDH was used as the internal control. Results are the average 
of triplicate 10µl reactions.  
2.3.5 Histopathological lesion scores 
Cecum and colon tissue from a subset of representative mice were evaluated for 
tissue damage because of infection. For this, a 1 cm section was collected from the cecum 
 
Table 1. Primer pair sequences for inflammatory markers tested. 
 
 
Gene Sense Sequence
IL-17 Forward 5'-AAG GCA GCA GCG ATC ATC C-3'
Reverse 5'-GGA ACG GTT GAG GTA GTC TGA G-3'
IFN-g Forward 5’-GGCCATCAGCAACAACATAAGCGT-3’
Reverse 5’-TGGGTTGTTGACCTCAAACTTGGC-3’
IL-1b Forward 5'-AAG GGC TGC TTC CAA ACC TTT GAC-3'
Reverse 5'-ATA CTG CCT GCC TGA AGC TCT TGT-3'
IL-23 Forward 5'-CCT GCT TGA CTC TGA CAT CTT C-3'
Reverse 5'-TGG GCA TCT GTT GGG TCT C-3'
IL-25 Forward 5'-CGGAGGAGTGGCTGAAGTGGAG-3'
Reverse 5'-ATGGGTACCTTCCTCGCCATG-3'
IL-33 Forward 5'-TCCAACTCCAAGATTTCCCCG-3'
Reverse 5'-CATGCAGTAGACATGGCAGAA-3'
IL-12(p40) Forward 5'-ACA TCA AGA GCA GTA GCA GTT C-3'
Reverse 5'-AGT TGG GCA GGT GAC ATC C-3'
IL-6 Forward 5'-TCC AGT TGC CTT CTT GGG AC-3'
Reverse 5'-GTG TAA TTA AGC CTC CGA CTT G-3'
KC Forward 5'-TCG CCA ATG AGC TGC GCT GTC-3'
Reverse 5'-GCT TCA GGG TCA AGG CAA GCC-3'
MIP-1a Forward 5ʹ-CAGCCAGGTGTCATTTTCCT-3'
Reverse 5ʹ-CTGCCTCCAAGACTCTCAGG-3'
MIP-2 Forward 5'-GAG CTT GAG TGT GAC GCC CCC AGG-3'
Reverse 5'-GTT AGC CTT GCC TTT GTT CAG TAT C-3'
GAPDH Forward 5'-GGAGGAACCTGCCAAGTATG-3'
Reverse 5'-TGGGAGTTGCTGTTGAAGTC-3'
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and colon at necropsy and fixed in 10% buffered formalin. Tissues were embedded in 
paraffin and sectioned prior to hematoxylin and eosin (H&E) staining, visualization and 
scoring at Iowa State University (Department of Veterinary Pathology). H&E-stained 
tissues were scored by a licensed pathologist blinded to treatment conditions for epithelial 
tissue damage, neutrophil infiltration, and mucosal edema as described (Shelby et al., 
2019).  
2.3.6 Myeloperoxidase activity assay 
Myeloperoxidase (MPO) activity was used to assess the levels of 
neutrophil/granulocyte infiltration in cecum tissue as outlined by Haarberg and 
colleagues with a few modifications (Haarberg et al., 2015). Cecum segments were 
collected at day 3 of C. difficile infection. Samples were stored in 15% DMSO and 0.1 
mM phenylmethylsulphonyl fluoride (PMSF), immediately frozen on dry ice, and stored 
at -80°C. Intestinal samples were thawed, blotted, trimmed to roughly 35 mg and 
homogenized in PBS with 0.1 mM PMSF and 0.02% hexadecyltrimethylammonium 
bromide (CTAB). Tissue homogenates were sonicated at an amplitude of 5, pulse on for 
4 seconds, pulse off for 1 second, for 20 seconds total. The tissue sonicates were then 
centrifuged at 250 X g for 15 min and the clarified supernatant used for the MPO assay. 
The reaction mixture consisted of 150 µl of supernatant, 50 µl of 0.78 mg/mL 3,3’,5,5’-
tetramethylbenzidine and 50 µl of 5 mM hydrogen peroxide in a total volume of 250 µl. 
Reactions were incubated at room temperature for 3 minutes and terminated by the 
addition of 50 µl of 2N H2SO4. Absorbance was measured at 405 nm and activity in each 
sample was compared to a standard curve generated from 2-fold serial dilutions of mouse 
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peripheral blood mononuclear cells and a CTAB negative control. The MPO activity was 
expressed as the relative units of enzyme per gram of wet weight of tissue. 
2.3.7 Statistical analysis 
Statistical analyses were performed using the GraphPad Prism version 8.4.2 for 
macOS, GraphPad Software, San Diego, California USA. Differences in percentage of 
body mass loss, C. difficile loads and toxin activity in feces were determined by Kruskal-
Wallis test with uncorrected Dunn’s test. Additionally, a Mantel-Cox log rank test was 
used to determine significant differences in level of mortality between C57BL/6J mice 
colonized with the three different donor’s microbiomes. Two sample unpaired t tests with 
Welch’s correction determined significance for changes in MPO activity and clinical 
sickness scores and one-way ANOVA with uncorrected Fisher’s LSD test for differences 
in histopathology scores. Significance of differences in cytokine levels between 
C57BL/6J and C3H/HeN mice were determined with a non-parametric Friedman test. 
Correlation between percentage of initial body mass loss and relative gene expression 
was determined with simple linear regression analysis. All significance was determined at 
p-value< 0.05. 
2.4 RESULTS 
2.4.1 C. difficile associated disease severity is influenced by mouse strain and 
microbiome. 
In initial studies, we colonized male and female gnotobiotic C57BL/6J and 
C3H/HeN mice with fecal samples from three healthy donors (MA, MB and MC; more 
details on the microbiome composition of these HMAmice can be found in Appendix A). 
These HMAmouse lines were bred under specific pathogen-free conditions and progeny 
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mice were tested for susceptibility to C. difficile infection following treatment with a 
combination of antibiotics known to induce susceptibility to C. difficile in other mouse 
models. Disease severity for the seven days following infection was monitored through 
daily measurement of body mass, and observation for symptoms of severe disease 
including diarrhea, hunched posture, difficulty breathing and loss of ambulation. After 
initial C. difficile exposure, we observed a clear distinction in disease severity following 
infection between C57BL/6J mice and C3H/HeN (Fig. 2.1a-c). Consistent with previous 
studies (Collins et al., 2015), C57BL/6J mice exhibited more severe disease as evidenced 
by 5-17% body mass loss, presence of diarrhea and mortality in a subset of mice 48-72 
hours following infection. In contrast, we observed little to no declines in body mass (0-
6%), nor any signs of overt disease or mortality in C3H/HeN (Fig. 2.1d).  
 
Figure 2.1. Differences in loss of body mass and mortality in different models of HMAmice. (a, b & 
c) Percentage of initial body mass was monitored daily after initial C. difficile exposure across the 
different mice strain-microbiome configurations. Points represent the medians and error bars represent 
the interquartile ranges. In a, n=13 C57BL/6J, n=12 C3H/HeN; in b, n=9 C57BL/6J, n=10 C3H/HeN; in 
c, n=10 C57BL/6J, n=13 C3H/HeN  (d & e) Differences in initial body mass on day 2, the most severe 
point of infection. Data is re-plotted from panels a-c; statistical significance was determined with 
Kruskal-Wallis test. (f) Probability of survival of C57BL/6J HMAmice following C. difficile challenge. 
Statistical significance was determined with Mantel-Cox log rank test.  
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In addition, the composition of donor microbiome used to colonize C57BL/6J also 
impacted disease severity. C57BL/6J mice colonized with microbiomes from donor A 
and B (MA and MB mice) showed a statistically significant decrease in body weight and 
mortality compared to mice colonized with microbiome from donor C (MC mice) which 
exhibited smaller decreases in body mass (6±3% (MC) vs 13±4% (MA) or 12±2% (MB)) 
at 48 hours, the point of infection at which mice had lost the largest percentage of body 
mass (Fig. 2.1e-f). Altogether, these data indicate that there are specific host and 
microbiome interactions that influence disease severity following C. difficile infection.  
 2.4.2 Differences in disease severity are not due to altered levels of C. difficile 
colonization or toxin production.  
One potential explanation for differences in disease severity between mouse lines 
could be due to differing levels of C. difficile or its toxin, as previous studies have 
demonstrated that mice with lower levels of C. difficile exhibit less severe disease 
(Reeves et al., 2011; Collins et al., 2015). Therefore, we sought to measure the levels of 
C. difficile colonization and toxin activity in our C. difficile infected mice to determine if 
there were differences in C. difficile colonization levels or toxin production that could 
explain disease outcome. To accomplish this, fecal samples were collected at different 
time points throughout the experiments and levels of C. difficile and toxin were 
measured. Examining levels of C. difficile in feces, we observed that all mouse strains 
had similar levels of C. difficile in feces on day 2 after infection. On day 4 of infection C. 
difficile levels in C3H/HeN were similar to (MC) or higher (MA) than in C57BL/6J mice 
(Fig. 2.2a). Similarly, we observed that levels of C. difficile toxin activity measured by 
cytotoxicity assays were not significantly different across the microbiome-mouse 
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configurations on day 2 or day 4 of infection (Fig. 2.2b). These data not only demonstrate 
the ability of C. difficile to colonize and produce toxin in all HMAmice tested but also 
indicate that additional factors are likely influencing disease outcome. 
 
 2.4.3 Mice with severe disease exhibit increased intestinal damage and 
neutrophil tissue infiltration. 
 After determining that differences in C. difficile colonization or toxin production 
was unlikely to determine differences in overt signs of disease, we decided to focus on 
better characterizing host responses to infection in different mouse-microbiome 
configurations. To streamline these studies, we focused on a single mouse-microbiome 
pair, microbiome MB-colonized C57BL/6J and C3H/HeN mice. In addition to 
monitoring body weight, clinical sickness scores were determined for these studies taking 
into consideration changes in behavior and stool characteristics. Consistent with body 
weight data from initial studies, C57BL/6J mice showed significantly higher disease 
Figure 2.2. Levels of CFU and toxin activity in feces from C57BL/6J and C3H/HeN HMAmice. 
(a) Levels of C. difficile relative toxin units per gram of feces on day 2 and 4 after initial infection 
determined with cytotoxicity assays. (b) Levels of C. difficile loads present on day 2 and 4 after 
initial infection determined with cytotoxicity assays. Statistical significance between mice groups 
was determined with Kruskal-Wallis test. Day 2 and day 4 sample collections belong to different 
experiments. ND indicates data not collected. Data was not collected from seven C57BL/6J-MC 
shown in Figure 2.1 as mice died prior to fecal sample collection. 
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scores in contrast with C3H/HeN where we observed little to no signs of disease (Fig. 
2.3a).  
 
Figure 2.3. Donor B-colonized (MB) C57BL/6J mice present elevated measures of disease 
severity in contrast to C3H/HeN mice. (a) Clinical sickness scoring was determined by evaluating 
percent of body weight loss, stool characteristics and changes in behavior. Scores ranged from least 
(0) to most (4) severe for each category adding to a total score of 12. Open circles indicate mice that 
died at a time before tissue harvesting for which no tissue was collected for MPO analysis. 
C3H/HeN n=13, C57BL/6J n=12 (b) Levels of neutrophil/granulocyte infiltration in cecum tissue 
was determined with myeloperoxidase activity assay. C3H/HeN n=13, C57BL6J n=10. Open 
triangles indicate the subset of mice used for histopathology analysis. (c) Fixed cecal and (d) colon 
tissue from a subset of C57BL/6J and C3H/HeN mice were blindly scored for epithelial cell loss, 
mucosal edema, and PMN infiltrate. Scores ranged from least (0) to most (4) severe for each 
measure. Statistical significance was determined with two sample unpaired t tests with Welch’s 
correction for changes in MPO activity and clinical sickness scores, and one-way ANOVA with 
uncorrected Fisher’s LSD test for differences in histopathology scores. 
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To evaluate the level of damage and cellular responses in mouse tissue as a 
consequence of infection we used MPO activity assay (Fig. 3b) and histopathological 
scoring (Fig. 2.3c-d). Histopathological analysis of cecal and colon tissue was performed 
on a representative subset of microbiome MB-colonized C57BL/6J and C3H/HeN mice 
(Fig. 2.3c-d). C3H/HeN mice showed low levels of polymorphonuclear leukocyte (PMN) 
infiltration, mucosal edema and no epithelial cell loss in cecal and colon tissue collected 
from mice at necropsy 72 hours after initial infection, while the majority of these markers 
of severe disease were elevated in the C57BL/6J mice. Cecal changes were more 
substantial than those in the colon, suggesting that at the time of necropsy (72 hours after 
infection), disease is localized in the cecum. Therefore, further analysis focused on 
characterizing inflammation in the cecum. 
Neutrophil infiltration was independently assayed in these mice by measuring the 
activity of myeloperoxidase (MPO), an enzyme that is produced at high levels by 
neutrophils. Consistent with the evidence of PMN infiltration in tissue, we observed 
higher levels of MPO activity in the cecum of C57BL/6J mice in comparison to 
C3H/HeN mice (Fig. 2.3b). These data correlate well with the differences in disease 
severity previously observed and indicate that C57BL/6J exhibit signs of a stronger ILC3 
response. 
 2.4.4 Differences in disease severity correlate with differences in expression 
of a subset of pro-inflammatory cytokines  
 The higher levels of epithelial damage and neutrophil activity in the cecum of sick 
mice led us to hypothesize that differences in host immune response could be responsible 
for modulating disease severity in the different mouse backgrounds. More specifically, 
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reduced disease severity in C3H/HeN mice could be due either to lower levels of 
induction of immune pathways that increase disease severity (ILC3 response) or due to 
higher levels of induction of immune pathways that decrease disease severity (ILC2 
response, and to a lesser extent ILC1 response.) Therefore, we identified 11 cytokine or 
chemokine analytes (IFN-g, IL-1b, IL-17A, Il-23, IL-25, IL-33, IL-12(p40), IL-6, KC, 
MIP-1a and MIP-2) from previous reports that have been identified as leading to 
increased or decreased disease severity during C. difficile infection to test our hypothesis.  
We compared levels of expression of these genes in C. difficile-infected mice to 
uninfected mice of the same strain background through RT-qPCR. We found that levels 
of all analytes with the exception of IL-1b, IL-33 and MIP-1a were induced to 
 
Figure 2.4. Expression of inflammatory markers upregulated in C57BL/6J mice. Levels inflammatory 
cytokines and chemokines associated with ILC type 3 (a) or type 1/2 (b) responses were measured from 
cecal tissue through RT-qPCR. Statistical significance (p<0.05) of differences in cytokine levels between 
C57BL/6J and C3H/HeN mice were determined with a non-parametric Friedman test. 
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significantly higher levels in the ceca of microbiome MB-colonized C57BL/6J mice 
compared to C3H/HeN mice (Fig. 2.4a). Interestingly, IL-1b was the only analyte that 
had increased levels in C3H/HeN mice cecum. When we examined relative expression of 
analytes more strongly associated with ILC type 1 or 2 responses that have been 
associated with protective mechanisms against severe disease, we observed that IL-25, 
IFNg, and IL-12(p40) were also significantly higher in C57BL/6J mice (Fig. 2.4b). 
Altogether, the results are consistent with increased immune activation in C57BL/6J mice 
relative to C3H/HeN mice.  
While we observed overall increased expression of pro-inflammatory cytokines and 
chemokines in C57BL/6J mice compared to C3H/HeN mice, we also observed levels of 
induction varied within these two populations of C. difficile-infected mice. We were 
interested in determining to what extent variations in levels of cytokine induction 
 
Figure 2.5. Inflammation markers correlate with loss of body mass. Simple linear 
regression tests showed association between relative gene expression of inflammatory 
markers and loss of body mass in C57BL/6J mice ceca. 
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paralleled differences in disease severity. To determine if these markers correlated with 
one of our previously observed measure of disease severity (body mass), we performed 
simple linear regression tests on every analyte against the percentage of body mass loss. 
We discovered that four analytes, IFN-g, IL-17A, IL-25 and MIP-2, had significant 
correlation (P < 0.05) between increased gene expression and increased body mass loss 
(Fig. 2.5). Altogether, this data indicates that a subset of immune markers correlate with 
body mass loss, one of our measures of disease severity, while the other markers show 
little correlation. 
2.5 DISCUSSION 
In the current study, we established lines of C57BL/6J mice and C3H/HeN 
HMAmice colonized with different fecal samples and demonstrated clear differences in 
disease severity due to differences in mouse background and microbiome composition. 
Two of three lines of C57BL/6J HMAmice exhibited severe disease and mortality during 
C. difficile infection that was consistent with previous studies of C. difficile infection in 
HMAmice (Collins et al., 2015); the third line of C57BL/6J HMAmice exhibited less severe 
disease, likely due to differences in microbiome composition that reduce disease severity. 
Studies of the effect of microbiome composition on disease severity in C57BL/6J mice 
will be the focus of future studies.  
  Unexpectedly, C3H/HeN infected mice showed little to no signs of overt disease 
despite similar levels of colonization with toxin-producing C. difficile; the similarities in 
disease presentation in these mice and asymptomatically colonized patients prompted 
further research on the mechanisms that could be protecting these mice from disease. Our 
initial studies focused on additional clinical markers of disease severity – epithelial 
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damage in infected mice and immune cell infiltration. We found that C57BL/6J infected 
mice exhibited significantly higher levels of epithelial damage and immune cell 
infiltration (neutrophil and other PMN) than C3H/HeN mice.  Neutrophil activation and 
recruitment are prominent characteristics of C. difficile infection which are often elicited 
by Type 3 ILC signaling (Saleh & Petri, 2019).  
We hypothesized that severe disease in C57BL/6J mice would correlate with 
increased levels of inflammatory markers associated with ILC Type 3 responses, while 
reduced disease severity in C3H/HeN mice could be due either to reduced levels of ILC 
Type 3 responses or upregulation of ILC Type 1 and 2 associated markers previously 
linked to reducing disease severity during C. difficile infection. Our results are consistent 
with the initial hypothesis, that reduced disease severity in C3H/HeN mice is more likely 
due to reduced levels of induction of pathways associated with increased disease severity 
rather than elevated expression of pathways associated with potentially protective effects 
during infection. 
Other potential differences between C3H/HeN and C57BL/6J mice could be 
contributing to the lower levels of induction observed in C3H/HeN mice. One potential 
mechanism could be that the kinetics of immune responses during C. difficile infection 
may vary between C3H/HeN and C57BL/6J mice, as differences in infection kinetics 
between C3H/HeN and C57BL/6J infected with Citrobacter rodentium have been 
previously reported (Carson et al., 2020). In C3H/HeN mice, earlier colonization of C. 
rodentium leads to earlier upregulation of IFNg and IL-22 that leads to more severe 
disease than is observed in C57BL/6J mice infected with C. rodentium. If similar 
colonization dynamics occurred during C. difficile infection, induction of these responses 
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could help to mitigate initial disease severity. We will test this hypothesis in future 
studies, where we plan to measure induction of cytokines at earlier points during 
infection. The current studies were designed using disease progression in C57BL/6J as a 
model for sampling, which is why tissue harvesting occurred three days after C. difficile 
exposure at the point when mice are just beginning to recover (Collins et al., 2015). Other 
potential mechanisms to investigate include differences in receptor intoxication of 
epithelial cells and differences in bile acid pools that may impact C. difficile 
pathogenicity.  
2.6 CONCLUSIONS 
These newly established HMAmouse models expand the tools available for 
studying how differences in microbiome-host interactions influence C. difficile disease 
progression. In addition to demonstrating that mouse genetic backgrounds have large 
impact on disease susceptibility, we also demonstrated that natural variation in 
microbiome composition can also influence disease outcome. While the results presented 
here clearly demonstrate differences in levels of inflammation during infection based 
upon both host genetic background and microbiome composition, future work is needed 
to determine the specific mechanisms that govern these differences. In the final chapter of 
this thesis, I will discuss potential future research directions to better understand how 
differences in responses to C. difficile infection may differentiate asymptomatic from 
symptomatic C. difficile infection.  
 
 
 
 
 
52 
2.7 REFERENCES 
Abt, M. C., Lewis, B. B., Caballero, S., Xiong, H., Carter, R. A., Sušac, B., Ling, L., 
Leiner, I., & Pamer, E. G. (2015). Innate Immune Defenses Mediated by Two ILC 
Subsets are Critical for Protection Against Acute Clostridium difficile Infection. Cell 
Host & Microbe, 18(1), 27–37.  
Abt, M. C., McKenney, P. T., & Pamer, E. G. (2016). Clostridium difficile colitis: 
Pathogenesis and host defence. Nature Reviews Microbiology, 14(10), 609–620.  
Auchtung, J. M., Preisner, E. C., Collins, J., Lerma, A. I., & Britton, R. A. (2020). 
Identification of Simplified Microbial Communities That Inhibit Clostridioides 
difficile Infection through Dilution/Extinction. MSphere, 5(4).  
Britanova, L., & Diefenbach, A. (2017a). Interplay of innate lymphoid cells and the 
microbiota. Immunological Reviews, 279(1), 36–51.  
Britanova, L., & Diefenbach, A. (2017b). Interplay of innate lymphoid cells and the 
microbiota. Immunological Reviews, 279(1), 36–51.  
Britton, R. A., & Young, V. B. (2012). Interaction between the intestinal microbiota and 
host in Clostridium difficile colonization resistance. Trends in Microbiology, 20(7), 
313–319.  
Buonomo, E. L., Cowardin, C. A., Wilson, M. G., Saleh, M. M., Pramoonjago, P., & 
Petri, W. A. (2016). Microbiota-Regulated IL-25 Increases Eosinophil Number to 
Provide Protection during Clostridium difficile Infection. Cell Reports, 16(2), 432–
443.  
Carson, D., Barry, R., Hopkins, E. G. D., Roumeliotis, T. I., García‐Weber, D., 
Mullineaux‐Sanders, C., Elinav, E., Arrieumerlou, C., Choudhary, J. S., & Frankel, 
 
 
53 
G. (2020). Citrobacter rodentium induces rapid and unique metabolic and 
inflammatory responses in mice suffering from severe disease. Cellular 
Microbiology, 22(1), e13126.  
Collins, J., Auchtung, J. M., Schaefer, L., Eaton, K. A., & Britton, R. A. (2015). 
Humanized microbiota mice as a model of recurrent Clostridium difficile disease. 
Microbiome, 3(1), 35.  
El Feghaly, R. E., Stauber, J. L., Deych, E., Gonzalez, C., Tarr, P. I., & Haslam, D. B. 
(2013). Markers of intestinal inflammation, not bacterial burden, correlate with 
clinical outcomes in Clostridium difficile infection. Clinical Infectious Diseases: An 
Official Publication of the Infectious Diseases Society of America, 56(12), 1713–
1721.  
Haarberg, K. M. (2015). Orally administered extract from Prunella vulgaris attenuates 
spontaneous colitis in mdr1a -/- mice. World Journal of Gastrointestinal 
Pharmacology and Therapeutics, 6(4), 223.  
Jose, S., & Madan, R. (2016). Neutrophil-mediated inflammation in the pathogenesis of 
Clostridium difficile infections. Anaerobe, 41, 85–90.  
Kelly, C. P., Becker, S., Linevsky, J. K., Joshi, M. A., O’Keane, J. C., Dickey, B. F., 
LaMont, J. T., & Pothoulakis, C. (1994). Neutrophil recruitment in Clostridium 
difficile toxin A enteritis in the rabbit. The Journal of Clinical Investigation, 93(3), 
1257–1265.  
Klose, C. S. N., Flach, M., Möhle, L., Rogell, L., Hoyler, T., Ebert, K., Fabiunke, C., 
Pfeifer, D., Sexl, V., Fonseca-Pereira, D., Domingues, R. G., Veiga-Fernandes, H., 
Arnold, S. J., Busslinger, M., Dunay, I. R., Tanriver, Y., & Diefenbach, A. (2014). 
 
 
54 
Differentiation of type 1 ILCs from a common progenitor to all helper-like innate 
lymphoid cell lineages. Cell, 157(2), 340–356.  
Leffler, D. A., & Lamont, J. T. (2015). Clostridium difficile Infection. New England 
Journal of Medicine, 372(16), 1539–1548.  
Martin, J. S. H., Monaghan, T. M., & Wilcox, M. H. (2016). Clostridium difficile 
infection: Epidemiology, diagnosis and understanding transmission. Nature Reviews. 
Gastroenterology & Hepatology, 13(4), 206–216.  
Reeves, A. E., Theriot, C. M., Bergin, I. L., Huffnagle, G. B., Schloss, P. D., & Young, 
V. B. (2011). The interplay between microbiome dynamics and pathogen dynamics 
in a murine model of Clostridium difficile Infection. Gut Microbes, 2(3), 145–158.  
Robinson, C. D., Auchtung, J. M., Collins, J., & Britton, R. A. (2014). Epidemic 
Clostridium difficile Strains Demonstrate Increased Competitive Fitness Compared 
to Nonepidemic Isolates. Infection and Immunity, 82(7), 2815–2825.  
Saleh, M. M., & Petri, W. A. (2019). Type 3 Immunity during Clostridioides difficile 
Infection: Too Much of a Good Thing? Infection and Immunity, 88(1).  
Seo, G.-Y., Giles, D. A., & Kronenberg, M. (2020). The role of innate lymphoid cells in 
response to microbes at mucosal surfaces. Mucosal Immunology, 13(3), 399–412.  
Serafini, N., Vosshenrich, C. A. J., & Di Santo, J. P. (2015). Transcriptional regulation of 
innate lymphoid cell fate. Nature Reviews. Immunology, 15(7), 415–428.  
Walker, J. A., Barlow, J. L., & McKenzie, A. N. J. (2013). Innate lymphoid cells—How 
did we miss them? Nature Reviews. Immunology, 13(2), 75–87.  
 
 
 
 
55 
 
CHAPTER 3. FURTHER CHARACTERIZATION OF IMPACTS OF HOST 
GENETICS AND MICROBIOME COMPOSITION ON C. DIFFICILE DISEASE 
SEVERITY 
3.1 OVERVIEW 
 C. difficile infection can cause a wide spectrum of clinical manifestations ranging 
from asymptomatic carriage or colonization to fulminant disease with toxic megacolon or 
death. Although the basis for these variations is not fully understood, continuously 
growing evidence indicate that interactions between host, microbiome and pathogen 
factors such as the activation of the innate mucosal immune signaling might have a 
significant role modulating disease severity (Collins & Auchtung, 2017; Abt et al., 2016). 
The development of appropriate mouse models that replicate differences in disease 
severity during C. difficile infection could provide essential pre-clinical tools to facilitate 
understanding of host-microbiome-pathogen interactions that reveal important insights 
into how these interactions impact C. difficile virulence and disease outcome in infected 
patients.    
Towards this goal, we have established HMAmouse models for which two 
phenotypes were observed, a state with little to no evidence of overt disease similar to 
asymptomatic colonization in patients and a state presenting symptomatic disease that 
varied in severity. These were largely based on the mouse genetic background (C3H/HeN 
and C57BL/6J respectively) and to a lesser degree on the specific microbiome they were 
colonized with. One major finding in our study was that, regardless of whether or not 
mice had symptomatic illness, they were colonized with comparable levels of C. difficile 
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and shed similar levels of C. difficile toxin in their feces, indicating that C. difficile had 
no obvious difficulty colonizing the intestinal tracts of these mice and subsequently 
producing its toxins. From this data, it was clear that there are both host genetic and 
microbiome-mediated mechanisms to reduce severity of disease when exposed to C. 
difficile toxins. Host genetic differences were apparent in comparisons between 
C3H/HeN and C57BL/6J mice colonized with microbiomes MA and MB, whereas 
microbiome-mediated differences were apparent in C57BL/6J colonized with different 
donor microbiomes (donor C compared to donors A and B).  
3.2 IMPACT OF MICROBIOME COMPOSITION ON DISEASE SEVERITY 
Several mechanisms by which the intestinal microbiota inhibit C. difficile have 
been proposed. These include the transformation of bile acids, which have impactful 
consequences on C. difficile spore germination and cell growth (Sorg and Sonenshein, 
2008, 2009); niche exclusion, where the use of non-toxigenic C. difficile strains could be 
preventing toxigenic strains colonization (Merrigan et al., 2003; Sambol et al., 2002); and 
the production of antimicrobial agents such as bacteriocins (Rea et al., 2010). However, 
these mechanisms are thought to primarily limit the initial levels of C. difficile 
colonization, and so are unlikely to be causing the variations in disease outcome we 
observed.  
Although the broad microbiome analysis we conducted did not show obvious 
trends that could explain the disease differences, the study was limited in sample size and 
did not covered the progression of disease. Future studies to characterize these 
differences will take advantage of a more extensive 16S rRNA gene sequencing to 
consider changes in microbiome composition over more time points from the beginning 
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of disease, with a specific emphasis on how differences in the abundance of bacteria that 
produce short chain fatty acids (SCFA) change over the course of disease. Previous 
studies have found that SCFA have been associated with modulation of host immune 
system and metabolism (Correa-Oliveira et al., 2016; Koh et al., 2016). Several studies 
have observed that a drastic reduction in SCFA after antibiotic treatments increase 
susceptibility to CDI (Antharam et al., 2013; Theriot et al., 2014), and a restoration of 
butyrate concentrations in the intestine have proven to attenuate disease severity in mice 
(Fachi et al., 2019). This data indicates that SCFA-producing bacteria have the potential 
to be used in protective strategies against CDI. We will also use microbiome transfer 
experiments to provide clearer mechanistic insights into how microbiome composition 
may impact disease severity. 
3.3 IMPACT OF HOST IMMUNE RESPONSE ON DISEASE SEVERITY 
 In addition to differences in overt signs of disease, one prominent difference that 
we observed in our study was differences in the levels of neutrophil activity in the ceca of 
the mice. As was consistent with differences in disease severity between C3H/HeN and 
C57BL/6J mice, there was little neutrophil infiltration in C3H/HeN mice and elevated 
neutrophil infiltration in C57BL/6J mice. To further understand potential mechanisms for 
differences in disease presentation, we measured differences in expression of several pro-
inflammatory cytokines between C3H/HeN and C57BL/6J mice. Cytokines were selected 
based upon previously reported roles in disease progression in C57BL/6J mice (Saleh and 
Petri, 2019; Abt et al., 2016). Consistent with differences in disease presentation, several 
pro-inflammatory cytokines were significantly elevated in C57BL/6J mice compared to 
C3H/HeN mice on day 3 of infection. Levels of cytokines were measured on day 3 of 
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infection, which immediately follows the point of largest body mass loss during infection 
in C57BL/6J mice. Only one cytokine, IL-1b, was significantly elevated in C3H/HeN 
mice. While these studies demonstrated reduced induction of pro-inflammatory 
mechanisms, these studies failed to provide broader insights into the underlying 
mechanisms that contribute to these differences. As described in the discussion for 
Chapter 2, one hypothesis is that the kinetics of disease progression may differ between 
C3H/HeN and C57BL/6J mice. Doing more extensive analysis from the beginning of 
infection, including broader gene expression and proteomics analysis, could provide 
insights into whether this hypothesis is correct. Once we identify specific pathways, 
comparative genomics analysis could be performed to look at the differences between 
both mice strains and the correlations to disease severity at a deeper level.   
It is also possible that other mechanisms might have a more significant role in 
providing protection against CDI. C. difficile produces a paracrystalline surface protein 
array, known as the S-layer, composed of surface layer proteins (SLPs) (Ní Eidhin et al., 
2008). It has been demonstrated that SLPs have a role in binding of C. difficile in the 
gastrointestinal tract, but they could potentially have additional roles as virulence factors 
as it has been shown for other bacteria such as Campylobacter fetus and Aeromonas 
salmonicida (O’Brien et al., 2005; Grogono-Thomas et al., 2000; Sára & Sleytr, 2000). 
SLPs have also been associated to innate immune system mechanisms for recognition of 
C. difficile where they could be playing an important role for activating the inflammatory 
responses (Ryan et al., 2011). Therefore, we will also examine whether differences in 
SLPs receptors could play a role in modulating disease severity in our HMAmouse model. 
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Altogether, we believe the research described in this thesis has the potential to 
contribute in the understanding of microbe-host interactions that regulate susceptibility 
and disease outcome in the context of CDI and lead to the development of novel targeted 
treatments adjunct to antibiotics and preventative strategies. 
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APPENDIX A 
To produce HMAmice, we colonized germ-free C57BL/6J and C3H/HeN mice with 
microbiomes from three different healthy donors (Donor A, B and C). These mice were 
bred under specific-pathogen-free conditions and their microbiota was subsequently 
passed to their progeny. We collected fecal samples from different HMAmice progeny 
mice at 6-8 weeks of age in order to examine their microbial composition with 16S rRNA 
gene sequencing. DNA was extracted by bead beating fecal pellets with 0.1mm beads, 
followed by BioSprint 96 One-For-All Vet kit processing. DNA was then amplified in 
duplicate with Phusion polymerase using Illumina barcoded primers 515F and 806R 
(Collins et al., 2015), then sequenced on a MiSeq using 2 x 250 kits. Generated fastq files 
were processed by mothur 1.41.3, removing chimeras identified by uchime, mapping 
sequences against Silva release 132, and clustering OTUs at 99% identity (Schloss et al., 
2009). To remove sample bleedover, the median + quartile value for a given OTU in 74 
controls (Bacillus subtilis 168 or ZymoBIOMICS microbial community standard) were 
removed from all samples prior to rarefaction. The level of rarefaction was chosen to 
maximize the number of samples and the reads/sample.  
Beta diversity analysis from the bacterial communities formed in our HMAmouse 
models showed that the communities formed in HMAmice segregated primarily by human 
fecal donor sample (Fig. A1a). Communities from each human fecal donor sample vastly 
diverged from their respective human sample inoculum along axis 1 with 19.1-23.1% of 
variation explained. Additional separation was observed along axis 2 (10.8-17.8% of 
variation), which separated mice based primarily upon mouse genetic background (Fig. 
A1b-d),  although communities formed in microbiome C colonized mice were more 
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similar between C3H/HeN and C57BL/6J mouse strains than were communities formed 
in HMAmice colonized with the other two microbiomes (MA and MB). Analysis of alpha 
diversity measures indicated that communities formed in C3H/HeN mice had lower 
levels of total OTUs when colonized with all three human microbiomes and reduced 
Shannon Diversity in mice colonized with microbiomes B and C (Fig. A1e); the 
microbiome from donor A, which started with the highest overall diversity and number of 
OTUs, had the most dramatic reduction in diversity compared to the starting inoculum.  
 
The relative abundance of the top 20 bacterial genera shifted in both mouse 
strains from the initial inoculum (Fig. A2). One trend that was obvious for all HMAmice 
was an overall increase in the abundance of Bacteroides in all donor colonized mice 
 
Figure A1. Measurements of alpha and beta diversity from HMAmice. (a-d) Clustering of 
bacterial communities formed in different HMAmice colonized with three distinct healthy donor’s 
microbiomes based upon principal coordinates analysis (PCoA) of Sorensen dissimilarities (e) 
Measurements of number of OTUs observed and Shannon diversity from the different 
microbiome-mouse combinations. For mouse samples, n=12 replicates/HMAmouse line, except 
for C3H/HeN-MA, n=14; for donor inocula, n=3 technical replicates. In a-c, statistical 
significance of groupings was determined through PERMANOVA. 
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compared to the starting inoculum. We also observed a reduction in levels of 
Agathobacter, a genus of Lachnospiraceae, in donor B and C colonized mice compared 
to the inoculum. Of note, Donor A colonized mice had lower overall levels of 
Bacteroides and increased in Muribaculaceae compared to donor B and C-colonized 
mice. 
 
To better understand the differences in beta-diversity that we observed between 
C3H/HeN and C57BL/6J mice colonized with the same fecal samples that we observed in 
Fig. A1, we used Mann-Whitney testing to identify genera among the top 20 most 
abundant genera that differed significantly between C3H/HeN and C57BL/6J mice when 
 
Figure A2. Top 20 taxa that differ significantly between HMAmice and fecal inocula. Stacked 
bar plots showing the relative abundance of bacterial genera of replicate fecal inocula and 
HMAcolonized mice distinct communities. Data are relative abundances of sequences assigned at 
the genus level from inoculum, n=3; C3H/HeN-MA, n=14; C3H/HeN-MB and MC, n=12; 
C57BL/6J-MA, MB and MC, n=12. 
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colonized with the same fecal sample. While there were several differences that were 
unique to each donor microbiome (Figure A3), we also observed trends consistent across 
all three fecal donor samples that may indicate selection imposed by host genetic 
background. Specifically, we observed significantly higher levels of Alistipes and 
Turicibacter in the C57BL/6J mice and higher levels of Blautia in C3H/HeN colonized 
with microbiomes A and C. As mentioned above, the proportions of Bacteroides species 
was elevated compared to the starting inoculum in all HMAmice, with Bacteroides species 
constituting 12-60% of reads detected. Overall, we did not observe obvious patterns that 
could be linked to differences in CDI disease severity and further research is needed to 
draw definitive conclusions. 
 
 
 
Figure A3. Top 20 genera that differ significantly between C3H/HeN and C57BL/6J 
HMAmice. Significant taxa that differentiated between C3H/HeN and C57BL/6J HMA mice 
organized by donor’s microbiome. The OTUs are classified to the genus level and significance 
(p<0.05) was determined with Mann-Whitney test. 
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